The FDA record for P990004 identifies Ferrosan Meidcal Devices A/S as the applicant for SURGIFOAM Absorbable Gelatin Sponge, USP, classified as an absorbable hemostatic agent, collagen based, in device class 3 under regulation number 878.4490, with the advisory committee described as General, Plastic Surgery. The original approval, dated 30 September 1999, states an indication for surgical procedures, excluding urologic, ophthalmic and neurologic procedures, for hemostasis when control of capillary, venous and arteriolar bleeding by pressure, ligature and other conventional procedures is ineffective or impractical. The supplied portfolio snapshot lists two linked PMA records, both with an approval decision, and the record sample contains the original approval and one supplement. [1][2]
The applicant and the approved device
The applicant name appears in the FDA filing as Ferrosan Meidcal Devices A/S, with a filing address of Sydmarken 5, Soeborg, and the trade name SURGIFOAM Absorbable Gelatin Sponge, USP. The generic name recorded is Agent, absorbable hemostatic, collagen based, and the product code is LMF. The filing carries a docket number of 99M-4776 for the original approval. [2]
Ferrosan Medical Devices describes itself as developing and manufacturing medical devices for haemostasis and biopsy procedures, and states that its gelatin-based haemostatic products are marketed under the SURGIFLO, SPONGOSTAN and SURGIFOAM trademarks through a partnership with Johnson & Johnson, which it says is responsible for global sales and distribution in more than 100 countries while Ferrosan remains the legal manufacturer. That distribution arrangement is the company's own published description, not an FDA finding. [10]
Dated filing examples
The original PMA P990004 was received on 22 January 1999 and approved on 30 September 1999, with no supplement number and no expedited review flag. The later record in the sample is supplement S080, a Normal 180 Day Track submission received on 25 March 2026 and approved on 18 September 2026, with a supplement reason of Change Design/Components/Specifications/Material and an approval statement referring to thinning of inner tray foil. [1][2]
The two records are the only entries in the supplied record sample, and both carry an approval decision. The snapshot's decision counts likewise show two approvals across the two linked records, all on the PMA pathway. These figures describe the supplied filings as of the snapshot date and are not a measure of total company portfolio, sales or safety performance. [1][2]
Product forms and published descriptions
Ferrosan Medical Devices lists SURGIFOAM Sponge for the United States and Canada and SURGIFOAM Powder for the same markets among its product categories, alongside SURGIFLO and SPONGOSTAN entries for other regions. The company's sponge page lists SURGIFOAM Absorbable Hemostatic Gelatin Sponges, USP, in specified sizes, including an oral sponge of 1cm x 1cm x 1cm and a size 12-7 sponge of 2cm x 6cm x 0.7cm, and notes that not all SURGIFOAM sponges may be approved for use outside the United States and Canada. [8][9]
A Johnson & Johnson MedTech product page describes SURGIFOAM Absorbable Gelatin Products in sponge and powder forms. These are the publisher’s product descriptions; the cited FDA filings record the particular applications and changes discussed above. [6]
What the record does and does not establish
The FDA entries establish the applicant identity, the device classification and regulation number, the original indication statement and the two dated decisions. They do not establish corporate ownership, headquarters, certifications, customers or commercial availability, and the filing address is not treated here as a headquarters. The relationship between Ferrosan and Johnson & Johnson is described only as the company itself publishes it. [1][2][10]

